Figure 7.
Effects of the MEK inhibitor U0126 (10 µM) on sorafenib (0.1 µM)-induced migration of different human bladder carcinoma cell lines (RT4, T24, J82). The quantitative analysis (means ± SEM) of five experiments are shown. *P < 0.05 versus control (anova /Bonferroni).